Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells.

Return to Grants

Grant Award Details

Grant Number:
DISC2-14096
Investigator(s):
Name:
Type:
PI

Human Stem Cell Use:
Award Value:
$1,450,876
Status:
Active

Grant Application Details

Application Title:

Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells.

Public Abstract:
Research Objective

Novel selective pharmacological strategy targeting senescent lung stem cells

Impact

Idiopathic pulmonary fibrosis along with other interstitial and age-related lung diseases

Major Proposed Activities

  • Chracterize senescence cells, including senescent stem and progenitor cells in the lung of patients affected by idiopathic pulmonary fibrosis
  • Screening of a Rubedo Life Science library of senolytic small molecules prodrug on Idiopathic pulmonary fibrosis primary cells
  • Development and charcterization of a humanized mouse model based on the primary IPF senescent cells characterized in Activity 1
  • Pharmacological characterization of the lead senolytic compound
  • Efficacy studies of the lead senolytic compound on the humanized IPF model
Statement of Benefit to California:
Progressive pulmonary fibrosis is an age-related degenerative interstitial lung disease that affects an increasing number of population in California and worldwide. The reasons of this increase include a growing aging population, decreased air quality due to increased air pollution, partially driven by climate change, and more recently by the impact of the virus SARS-CoV2 on COVID19 survivors. The proposed therapy will benefit less privileged aging populations affected by environmental hazards..